InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (9 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
9
T+90 hit rate
0%
T+90 mean return
-3.5%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by de los Pinos Elisabet, Executive. Officer active across 1 company, notably Aura Biosciences, Inc.. In total, 18 filings have been recorded. Split: 0 buy · 9 sells. Total volume traded: €807k. History available since 28 October 2021. The latest transaction was filed on 20 January 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations18 total
16,928 shares@ US$4.868.2% of flowCommon StockSEC:0001193125-26-016938:0
9,049 shares@ US$6.355.2% of flowCommon StockSEC:0001193125-25-256619:0
10,948 shares@ US$5.075.3% of flowCommon StockSEC:0000950170-25-081615:0
20,221 shares@ US$7.754117.4% of flowCommon StockSEC:0000950170-25-022651:0
194,320 shares0Common StockSEC:0000950170-25-013830:0
15,955 shares@ US$7.670413.7% of flowCommon StockSEC:0000950170-25-007495:0
9,200 shares@ US$10.737810.6% of flowCommon StockSEC:0000950170-24-118478:0
24,992 shares@ US$2.747.4% of flowCommon StockSEC:0000950170-24-115729:0
5,474 shares@ US$5.763.3% of flowCommon StockSEC:0000950170-24-110933:0
162,935 shares0Common StockSEC:0000950170-24-010460:0
15,853 shares@ US$7.641513.0% of flowCommon StockSEC:0000950170-24-006988:0
3,800 shares@ US$2.741.1% of flowCommon StockSEC:0000950170-23-060499:0
7,449 shares@ US$12.02999.7% of flowCommon StockSEC:0000950170-23-060499:1
9,586 shares@ US$6.83067.2% of flowCommon StockSEC:0000950170-23-057640:0
121,875 shares0Common StockSEC:0000899243-23-002434:0
5,706 shares@ US$12.45748.3% of flowCommon StockSEC:0000899243-22-034836:0
4,552 shares0Common StockSEC:0000899243-21-042362:0
74,357 shares0Common StockSEC:0000899243-21-042090:0
18 of 18 declarations
About de los Pinos Elisabet
Elisabet de los Pinos is an executive at Aura Biosciences, Inc. Her role involves various responsibilities within the company, contributing to its strategy and development. Elisabet brings valuable expertise in the biopharmaceutical sector.
